Literature DB >> 7906872

Sequential intrastriatal grafting of allogeneic embryonic dopamine-rich neuronal tissue in adult rats: will the second graft be rejected?

W M Duan1, H Widner, A Björklund, P Brundin.   

Abstract

An important issue in clinical neural grafting is whether a second instriatial allograft can survive well in a patient who has received an allograft before. In this study, the survival, immunogenicity and function of intrastriatal grafts of allogeneic or syngeneic embryonic dopamine-rich tissue in rats which had previously received either an intrastriatal allo- or syn-graft or sham injections were examined. The first graft tissue was taken from inbred Lewis or Sprague-Dawley rat embryos and grafted into an intact striatum of adult Sprague-Dawley rats subjected to a unilateral 6-hydroxydopamine lesion on the contralateral side. Eight weeks after the first transplantation, either allogeneic or syngeneic tissue was grafted as dissociated tissue into the dopamine depleted striatum. The function of the second grafts was assessed by rotational asymmetry at two different time points, i.e. eight and 14 weeks after the second transplantation. There were significant reductions of rotational asymmetry in all groups over time, but no significant difference between groups. Tyrosine hydroxylase immunocytochemistry was used to assess dopamine cell survival and graft size. Statistical analysis revealed no significant differnce in the mean number of tyrosine hydroxylase immunoreactive cells or the mean volume of the second grafts placed on the right side (lesioned side) between groups. Monoclonal antibodies were used to evaluate cellular immune reactions and the major histocompatibility complex class I and class II expression in and around grafts. No major histocompatibility complex class I expression was seen in any of the graft combinations. The expression of the major histocompatibility complex class II antigens was generally higher in patches in and around the second allograft of rats which had previously received an allograft than that in and around any other type of grafts. However, the expression of the major histocompatibility complex class II antigens was low throughout the grafts and did not appear as marked perivascular infiltrates. All the major histocompatibility complex class II positive cells displayed a microglia-like morphology, supported by the parallel microglia and macrophage-specific OX-42 immunostaining. The results show that there is no marked on-going immune reactions in or around the implantation site in any group fourteen weeks after a second transplantation. It may be concluded, therefore, that sequential allografting, using stereotaxic implantation of dissociated embryonic neural tissue into the striatal parenchyma, is possible to perform without a major risk of graft rejection, provided that an atraumatic technique is used.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7906872     DOI: 10.1016/0306-4522(93)90061-j

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  7 in total

Review 1.  Cell therapy in Parkinson's disease.

Authors:  Olle Lindvall; Anders Björklund
Journal:  NeuroRx       Date:  2004-10

Review 2.  Immune problems in central nervous system cell therapy.

Authors:  Roger A Barker; Håkan Widner
Journal:  NeuroRx       Date:  2004-10

3.  Temporal pattern of host responses against intrastriatal grafts of syngeneic, allogeneic or xenogeneic embryonic neuronal tissue in rats.

Authors:  W M Duan; H Widner; P Brundin
Journal:  Exp Brain Res       Date:  1995       Impact factor: 1.972

4.  Protection of the neostriatum against excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells.

Authors:  A Martínez-Serrano; A Björklund
Journal:  J Neurosci       Date:  1996-08-01       Impact factor: 6.167

5.  Transplantation of human retinal pigment epithelium cells in the treatment for Parkinson disease.

Authors:  Feng Yin; Zeng-Min Tian; Shuang Liu; Quan-Jun Zhao; Rui-Min Wang; Li Shen; Jeffery Wieman; Ying Yan
Journal:  CNS Neurosci Ther       Date:  2012-12       Impact factor: 5.243

Review 6.  The immunogenicity of midbrain dopaminergic neurons and the implications for neural grafting trials in Parkinson's disease.

Authors:  Shamma Qarin; Sarah K Howlett; Joanne L Jones; Roger A Barker
Journal:  Neuronal Signal       Date:  2021-09-13

7.  Pre-immunization with an intramuscular injection of AAV9-human erythropoietin vectors reduces the vector-mediated transduction following re-administration in rat brain.

Authors:  Chun Yang; Wei-Hua Yang; Sha-Sha Chen; Bao-Feng Ma; Bin Li; Tao Lu; Ting-Yu Qu; Ronald L Klein; Li-Ru Zhao; Wei-Ming Duan
Journal:  PLoS One       Date:  2013-05-08       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.